Announced details
EPファーマライン and SUZUKEN Group entered into a basic agreement on 14 May 2026, and will build on those discussions through the current initiative. EPファーマライン is a member of the EPS Group. The parties will discuss and consider options, including a review of their capital structure, but no decisions have been made as of the present time.
SUZUKEN CO.,LTD., headquartered in Nagoya, operates businesses including wholesale distribution of prescription pharmaceuticals, research and development support, manufacturing, sales, distribution, and regional and home healthcare. EPSホールディングス, headquartered in Shinjuku-ku, Tokyo, provides more than 50 services in the pharmaceutical, medical and healthcare fields, including CRO, SMO and CSO services. 株式会社EPNextS oversees the clinical-trial and post-marketing businesses of the EPS Group. 株式会社EPファーマライン, headquartered in Toshima-ku, Tokyo, provides services to the pharmaceutical, medical, medical-device and healthcare industries.
AI-MS is a trademark registered by 株式会社コラボスクエア. Registration number and expiration date: not disclosed
EPSホールディングス: 2-1 Tsukudo Hachimancho, Tsukudo Terrace, Shinjuku-ku, Tokyo; SUZUKEN: 8 Higashikatabatacho, Higashi-ku, Nagoya; EPNextS: 2-1 Tsukudo Hachimancho, Tsukudo Terrace, Shinjuku-ku, Tokyo; EPファーマライン: Ikebukuro West Park Building, 3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo
The parties are discussing and considering the deepening of their business alliance and the structure of their capital relationship. The specific impact on financial results: not disclosed
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Medical Contact Center, AI-MS, CS Assist Line, Multichannel support for pharmaceutical companies |
| Counterparty | SUZUKEN CO.,LTD., EPSホールディングス株式会社, 株式会社EPNextS, 株式会社EPファーマライン |
| Counterparty overview | SUZUKEN CO.,LTD., headquartered in Nagoya, operates businesses including wholesale distribution of prescription pharmaceuticals, research and development support, manufacturing, sales, distribution, and regional and home healthcare. EPSホールディングス, headquartered in Shinjuku-ku, Tokyo, provides more than 50 services in the pharmaceutical, medical and healthcare fields, including CRO, SMO and CSO services. 株式会社EPNextS oversees the clinical-trial and post-marketing businesses of the EPS Group. 株式会社EPファーマライン, headquartered in Toshima-ku, Tokyo, provides services to the pharmaceutical, medical, medical-device and healthcare industries. |
| Relationship with the Company | EPファーマライン and SUZUKEN Group entered into a basic agreement on 14 May 2026, and will build on those discussions through the current initiative. EPファーマライン is a member of the EPS Group. The parties will discuss and consider options, including a review of their capital structure, but no decisions have been made as of the present time. |
| Contract Date | 14 May 2026 (basic agreement) |
| Applicable area | Medical and Healthcare, Support for pharmaceutical companies, Post-marketing activities for pharmaceuticals, medical devices and other products, Medical institutions, regional healthcare and home healthcare |
| Registration number and expiry date | AI-MS is a trademark registered by 株式会社コラボスクエア. Registration number and expiration date: not disclosed |
| Location | EPSホールディングス: 2-1 Tsukudo Hachimancho, Tsukudo Terrace, Shinjuku-ku, Tokyo; SUZUKEN: 8 Higashikatabatacho, Higashi-ku, Nagoya; EPNextS: 2-1 Tsukudo Hachimancho, Tsukudo Terrace, Shinjuku-ku, Tokyo; EPファーマライン: Ikebukuro West Park Building, 3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo |
| Impact on Business Performance | The parties are discussing and considering the deepening of their business alliance and the structure of their capital relationship. The specific impact on financial results: not disclosed |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine the companies’ customer touchpoints, expertise, business platforms and digital technologies to create new value in the medical and healthcare fields, strengthen competitiveness and achieve sustainable growth.